SCHEMBL17084181

SCHEMBL17084181

CC(C)C(CS(C)(=O)=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.53
KDM4E B2RXH2 1/20 0.41
GMNN O75496 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
PMP22 Q01453 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KCNA3 P22001 1/20 0.38
SLC6A3 Q01959 2/20 0.38
AOC3 Q16853 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
GRIA4 P48058 1/20 0.37
CCR5 P51681 1/20 0.37
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21536076 0.81 TAAR1 (0.50) TAAR1KDM4EGMNNALDH1A1LMNA
SCHEMBL17086665 0.79 TAAR1 (0.50) TAAR1KDM4EGMNNALDH1A1LMNA
SCHEMBL17086715 0.79 TAAR1 (0.50) TAAR1KDM4EGMNNALDH1A1LMNA
SCHEMBL13881582 0.79 HTR2A (0.43) TAAR1ALDH1A1LMNAPOLBTDP1
SCHEMBL11743507 0.78 CES2 (0.39) TAAR1KDM4EGMNNALDH1A1LMNA
SCHEMBL17947367 0.77 ESR1 (0.42) TAAR1KDM4EGMNNALDH1A1LMNA
SCHEMBL9298053 0.73 GBA1 (0.49)
SCHEMBL11687409 0.73 LMNA (0.54) KDM4EGMNNALDH1A1LMNAPOLB
SCHEMBL28141011 0.73 GBA1 (0.49)
SCHEMBL28111816 0.73 LMNA (0.54) KDM4EGMNNALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10919885-B2 Compounds and uses thereof YUMANITY THERAPEUTICS, INC. (US) 2021-02-16 US disclosed
US-20190330198-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2019-10-31 US disclosed
US-9226922-B2 Compounds that are ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2016-01-05 US disclosed
US-20150258074-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919885-B2 Compounds and uses thereof NLN, ACHE, CLN6 TAAR1 2733/4885KDM4E 2853/4885GMNN 3708/4885
US-20190330198-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 TAAR1 2733/4885KDM4E 2853/4885GMNN 3708/4885
US-20150258074-A1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MAPK1, MAPK4, MAP3K20 TAAR1 3007/4885KDM4E 2166/4885GMNN 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.